Shareholding for the Period Ended March 31, 2017
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here18-04-2017
18-04-2017
Sanofi to boost volumes, exports as price control hits margins
With price controls continuing to crimp margins, Sanofi India expects a muted growth in the domestic market in 2017 and therefore the company will be focusing on volumes as well as exports. We...16-04-2017
Compliance Certificate - Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the compliance certificate for the period October 1, 2016 to March 31, 2017.13-04-2017
Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March 2017
Pursuant to Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Certificate of M/s. S. N. Ananthasubramanian & Co., Company Secretaries for the half year ended 31st March 2017.13-04-2017
Nikhilesh Kalra to lead Sanofi's CHC business in India, South Asia
Global healthcare firm Sanofi has appointed Nikhilesh Kalra as the general manager of its consumer healthcare business in India, South Asia12-04-2017
Publication Of Notice Of Annual General Meeting And E-Voting Information
Please find enclosed copies of the Notice of the Annual General Meeting and E-voting information of the Company published today, in newspapers, Business Standard and Sakal.08-04-2017
Notice Of Annual General Meeting
We enclose herewith copy of Notice convening Annual General Meeting of the Company to be held on 5th May 2017.07-04-2017
Sanofi and Regeneron's eczema drug gets FDA nod
Global healthcare company Sanofi and Regeneron Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injection to patients suffering from...29-03-2017
Clarifies on News Item
With reference to the news flashed on www.reuters.com dated March 29, 2017 quoting "FDA Approves Regeneron, Sanofi $37,000 per year eczema drug", Sanofi India Ltd has submitted to BSE a copy of Clarification is enclosed.29-03-2017
Clarification sought from Sanofi India Ltd
The Exchange has sought clarification from Sanofi India Ltd on March 29, 2017, with reference to the news flashed on www.reuters.com dated March 29, 2017 quoting "FDA Approves Regeneron, Sanofi $37,000 per year eczema drug"The reply is awaited.29-03-2017